NZ702136A - St2l antagonists and methods of use - Google Patents
St2l antagonists and methods of useInfo
- Publication number
- NZ702136A NZ702136A NZ702136A NZ70213613A NZ702136A NZ 702136 A NZ702136 A NZ 702136A NZ 702136 A NZ702136 A NZ 702136A NZ 70213613 A NZ70213613 A NZ 70213613A NZ 702136 A NZ702136 A NZ 702136A
- Authority
- NZ
- New Zealand
- Prior art keywords
- methods
- antagonists
- st2l
- st2l antagonists
- fragments
- Prior art date
Links
- 239000005557 antagonist Substances 0.000 title abstract 3
- 101000852968 Homo sapiens Interleukin-1 receptor-like 1 Proteins 0.000 abstract 1
- 101000680096 Homo sapiens Transmembrane emp24 domain-containing protein 1 Proteins 0.000 abstract 1
- 102100022243 Transmembrane emp24 domain-containing protein 1 Human genes 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 102000040430 polynucleotide Human genes 0.000 abstract 1
- 108091033319 polynucleotide Proteins 0.000 abstract 1
- 239000002157 polynucleotide Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
- Y10S530/809—Fused cells, e.g. hybridoma
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Catching Or Destruction (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NZ729913A NZ729913A (en) | 2012-04-30 | 2013-04-29 | St2l antagonists and methods of use |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261640407P | 2012-04-30 | 2012-04-30 | |
| US201261640238P | 2012-04-30 | 2012-04-30 | |
| US13/798,226 US9212227B2 (en) | 2012-04-30 | 2013-03-13 | ST2L antibody antagonists for the treatment of ST2L-mediated inflammatory pulmonary conditions |
| US13/798,204 US9090694B2 (en) | 2012-04-30 | 2013-03-13 | ST2L antibody antagonists |
| PCT/US2013/038637 WO2013165894A2 (en) | 2012-04-30 | 2013-04-29 | St2l antagonists and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ702136A true NZ702136A (en) | 2017-03-31 |
Family
ID=49477497
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ702136A NZ702136A (en) | 2012-04-30 | 2013-04-29 | St2l antagonists and methods of use |
| NZ729913A NZ729913A (en) | 2012-04-30 | 2013-04-29 | St2l antagonists and methods of use |
| NZ74022113A NZ740221A (en) | 2012-04-30 | 2013-04-29 | St2l antagonists and methods of use |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ729913A NZ729913A (en) | 2012-04-30 | 2013-04-29 | St2l antagonists and methods of use |
| NZ74022113A NZ740221A (en) | 2012-04-30 | 2013-04-29 | St2l antagonists and methods of use |
Country Status (37)
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10053513B2 (en) | 2009-11-30 | 2018-08-21 | Janssen Biotech, Inc. | Antibody Fc mutants with ablated effector functions |
| SI2506871T1 (sl) * | 2009-11-30 | 2016-12-30 | Janssen Biotech, Inc. | Mutanti Fc protitelesa z odstranjenimi efektorskimi funkcijami |
| US9212227B2 (en) * | 2012-04-30 | 2015-12-15 | Janssen Biotech, Inc. | ST2L antibody antagonists for the treatment of ST2L-mediated inflammatory pulmonary conditions |
| AR091069A1 (es) | 2012-05-18 | 2014-12-30 | Amgen Inc | Proteinas de union a antigeno dirigidas contra el receptor st2 |
| JO3532B1 (ar) | 2013-03-13 | 2020-07-05 | Regeneron Pharma | Ų§ŁŲ£Ų¬Ų³Ų§Ł Ų§ŁŁ Ų¶Ų§ŲÆŲ© ŁŁ Ų¶Ų§ŲÆ Ų§ŁŲŖŲ±ŁŁŁŁŁ-33 ŁŲ§Ų³ŲŖŲ¹Ł Ų§ŁŲ§ŲŖŁŲ§ |
| MX364591B (es) | 2013-03-15 | 2019-05-02 | Regeneron Pharma | Antagonistas de il-33 y usos de estos. |
| EP3092253B1 (en) | 2014-01-10 | 2021-03-17 | AnaptysBio, Inc. | Antibodies directed against interleukin-33 (il-33) |
| CA2946511C (en) | 2014-04-21 | 2023-08-22 | The Childen's Hospital Of Philadelphia | Compositions and methods for treating cytokine-related disorders |
| AU2015280436A1 (en) | 2014-06-23 | 2017-02-02 | Bionomics, Inc. | Antibodies that bind LGR4 |
| CN107109494B (zh) | 2014-11-10 | 2023-10-27 | č±Ŗ夫čæĀ·ē½ę°ęéå ¬åø | Il-33ä»åƼåē¾ē ēę²»ēę¹ę³åčÆęę¹ę³ |
| CA2960297A1 (en) | 2014-11-10 | 2016-05-19 | Genentech, Inc. | Anti-interleukin-33 antibodies and uses thereof |
| EP3265493B1 (en) | 2015-03-02 | 2024-01-10 | 180 Therapeutics LP | Method of treating a localized fibrotic disorder using an il-33 antagonist |
| JP7114460B2 (ja) | 2015-06-26 | 2022-08-08 | ćµććć£ć»ćć¤ćŖććÆćććøć¼ | ć¢ććÆćć¼ćć«ęļ¼©ļ¼¬ļ¼ļ¼ļ¼²ļ¼”ļ½ļ¼°ęä½ |
| SG11201805900YA (en) * | 2016-01-14 | 2018-08-30 | Anaptysbio Inc | Inhibition of allergic reaction using an il-33 inhibitor |
| EP3241845A1 (en) | 2016-05-06 | 2017-11-08 | MAB Discovery GmbH | Humanized anti-il-1r3 antibodies |
| US20190225682A1 (en) * | 2016-09-02 | 2019-07-25 | 180 Therapeutics Lp | Method of treating localized fibrotic disorders using an il-33/tnf bispecific antibody |
| EP3506920A4 (en) * | 2016-09-02 | 2020-05-27 | 180 Therapeutics LP | METHOD FOR TREATING SYSTEMIC FIBROTIC DISEASES WITH A BISPECIFIC IL-33 / TNF ANTIBODY |
| JOP20190093A1 (ar) | 2016-10-28 | 2019-04-25 | Lilly Co Eli | Ų£Ų¬Ų³Ų§Ł Ł Ų¶Ų§ŲÆŲ© ŁŁ il-33 ŁŲ§Ų³ŲŖŲ®ŲÆŲ§Ł Ų§ŲŖŁŲ§ |
| TWI784988B (zh) | 2016-12-01 | 2022-12-01 | ē¾ååēå é«č„å ¬åø | ę²»ēē¼ēēēēę¹ę³ |
| UA126574C2 (uk) | 2017-02-10 | 2022-11-02 | ŠŠ¶ŠµŠ½ŠµŠ½ŃŠµŠŗ, ŠŠ½Šŗ. | ŠŠ½ŃŠøŃŃŠ»Š¾ ŠæŃŠ¾ŃŠø ŃŃŠøŠæŃŠ°Š·Šø, Š¹Š¾Š³Š¾ ŠŗŠ¾Š¼ŠæŠ¾Š·ŠøŃŃŃ ŃŠ° Š·Š°ŃŃŠ¾ŃŃŠ²Š°Š½Š½Ń |
| WO2018178076A1 (en) * | 2017-03-29 | 2018-10-04 | F. Hoffmann-La Roche Ag | Bispecific antigen binding molecule for a costimulatory tnf receptor |
| MX2019012171A (es) | 2017-04-13 | 2019-11-25 | Regeneron Pharma | Tratamiento e inhibicion de enfermedades pulmonares inflamatorias en pacientes que tienen alelos de riesgo en los genes que codifican la il33 e il1rl1. |
| EP3401332A1 (en) | 2017-05-08 | 2018-11-14 | MAB Discovery GmbH | Anti-il-1r3 antibodies for use in inflammatory conditions |
| MA51302A (fr) | 2017-12-21 | 2021-03-31 | Hoffmann La Roche | Anticorps se liant Ć hla-a2/wt1 |
| JP7418337B2 (ja) | 2018-02-09 | 2024-01-19 | ćøć§ćć³ćććÆļ¼ ć¤ć³ć³ć¼ćć¬ć¤ććć | ćć¹ćē“°čåŖä»ę§ēēę§ē¾ę£ć®ę²»ēę³åć³čØŗęę³ |
| IL277890B2 (en) | 2018-04-11 | 2024-03-01 | Regeneron Pharma | Methods for quantifying il-33 |
| SG11202104120VA (en) * | 2018-10-31 | 2021-05-28 | Delinia Inc | Multivalent regulatory t cell modulators |
| KR102353568B1 (ko) | 2018-11-14 | 2022-01-20 | ģ£¼ģķģ¬ ķ¬ė¦ģ¤ėÆøģ¤ | ģģ ģ±ģ“ ķ„ģė ķ c-Met ķģ²“ ėė ź·øģ ķģ ź²°ķ© ėØķø |
| CN110045131B (zh) * | 2019-06-14 | 2019-09-03 | čæåØ(äøęµ·)ēē©ē§ęęéå ¬åø | ēØäŗęµå®äŗŗil-33/st2éč·Æęå¶åēēē©å¦ę“»ę§ēę¹ę³ |
| EP4054711A1 (en) | 2019-11-04 | 2022-09-14 | MedImmune Limited | Methods of using il-33 antagonists |
| WO2021089559A1 (en) | 2019-11-04 | 2021-05-14 | Medimmune Limited | Anti il-33 therapeutic agent fpr treating renal disorders |
| PH12022552371A1 (en) | 2020-03-13 | 2023-12-18 | Genentech Inc | Anti-interleukin-33 antibodies and uses thereof |
| CN115315527A (zh) | 2020-03-13 | 2022-11-08 | å ē«å»ēęéå ¬åø | ēØäŗę²»ēil33äøååØé£é©ēä½åŗå ēåčÆč ēę²»ēę¹ę³ |
| IL296853A (en) | 2020-04-06 | 2022-11-01 | Medimmune Ltd | Treatment of acute respiratory distress syndrome with il-33 axis binding antagonists |
| IL298075A (en) * | 2020-05-12 | 2023-01-01 | Chia Tai Tianqing Pharmaceutical Group Co Ltd | St2 antigen binding protein |
| CN113501878B (zh) * | 2021-02-03 | 2022-12-02 | åäŗ¬ęŗä»ē¾åēē©ē§ęęéå ¬åø | éåƹäŗŗtslpēå¤ē§ęä½åå ¶ēØé |
| TW202304965A (zh) | 2021-05-04 | 2023-02-01 | ē¾åč¾åē“ęÆå ¬åø | ęļ½ļ½ļ½ļ½ļ½ęé«ćęļ½ļ½ļ¼ļ¼ęé«åå ¶ä½æēØę¹ę³ |
| TW202322850A (zh) * | 2021-08-05 | 2023-06-16 | ē¾åē¾åē¦®ä¾å¤§č„å» | ęé«ęä½³å |
| EP4430072A1 (en) | 2021-11-10 | 2024-09-18 | Genentech, Inc. | Anti-interleukin-33 antibodies and uses thereof |
| WO2023160610A1 (en) * | 2022-02-24 | 2023-08-31 | Sinomab Bioscience Limited | Bispecific binding proteins against alarmins and uses thereof |
| CN115838425B (zh) * | 2022-08-31 | 2024-06-18 | é¦é½å»ē§å¤§å¦ | äøē§é¶åč”ē®”ē“§å¼ ē“ ii 1ååä½ē»čå¤ē¬¬äŗēÆēęä½åå ¶åŗēØ |
| WO2024062074A1 (en) | 2022-09-21 | 2024-03-28 | Sanofi Biotechnology | Humanized anti-il-1r3 antibody and methods of use |
| CN119841936B (zh) * | 2024-12-30 | 2025-09-30 | äøå½åäøē§å¦é¢å °å·å ½å»ē ē©¶ę(äøå½åØē©å«ēäøęµč”ē å¦äøåæå °å·åäøåæ) | ęéę“²ēŖēē ęÆp72čē½äøåę§åå éęä½5d2åå ¶åŗēØ |
Family Cites Families (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US5869620A (en) | 1986-09-02 | 1999-02-09 | Enzon, Inc. | Multivalent antigen-binding proteins |
| EP0281604B1 (en) | 1986-09-02 | 1993-03-31 | Enzon Labs Inc. | Single polypeptide chain binding molecules |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| ATE139258T1 (de) | 1990-01-12 | 1996-06-15 | Cell Genesys Inc | Erzeugung xenogener antikƶrper |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US6800738B1 (en) | 1991-06-14 | 2004-10-05 | Genentech, Inc. | Method for making humanized antibodies |
| US5932448A (en) | 1991-11-29 | 1999-08-03 | Protein Design Labs., Inc. | Bispecific antibody heterodimers |
| ES2341666T3 (es) | 1991-12-02 | 2010-06-24 | Medimmune Limited | Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos. |
| DK0672142T3 (da) | 1992-12-04 | 2001-06-18 | Medical Res Council | Multivalente og multispecifikke bindingsproteiner samt fremstilling og anvendelse af disse |
| JPH09506508A (ja) | 1993-12-03 | 1997-06-30 | ć”ćć£ć«ć« ćŖćµć¼ć ć«ć¦ć³ć·ć« | ēµęćēµåćæć³ććÆč³Ŗććć³ćććć |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| AUPO591797A0 (en) | 1997-03-27 | 1997-04-24 | Commonwealth Scientific And Industrial Research Organisation | High avidity polyvalent and polyspecific reagents |
| US5989830A (en) | 1995-10-16 | 1999-11-23 | Unilever Patent Holdings Bv | Bifunctional or bivalent antibody fragment analogue |
| US6103529A (en) | 1996-10-10 | 2000-08-15 | Life Technologies, Inc. | Animal cell culture media comprising peptides derived from rice |
| GB9727172D0 (en) | 1997-12-24 | 1998-02-25 | Univ Glasgow | Reagents specific for st2l and uses therefor |
| DE19819846B4 (de) | 1998-05-05 | 2016-11-24 | Deutsches Krebsforschungszentrum Stiftung des ƶffentlichen Rechts | Multivalente Antikƶrper-Konstrukte |
| GB9911569D0 (en) | 1999-05-18 | 1999-07-21 | Oxford Biomedica Ltd | Antibodies |
| US6323334B1 (en) * | 1999-09-24 | 2001-11-27 | Millennium Pharmaceuticals, Inc. | Nucleic acid molecules encoding a 103 gene product and uses therefor |
| WO2001070817A1 (en) | 2000-03-21 | 2001-09-27 | Medical & Biological Laboratories Co., Ltd. | Monoclonal antibody and method and kit for the immunoassay of soluble human st2 with the use of the same |
| ES2405944T3 (es) | 2000-11-30 | 2013-06-04 | Medarex, Inc. | Ćcidos nucleicos que codifican las secuencias de inmunoglobulina humana reorganizadas a partir de ratones transcromoscĆ³micos transgĆ©nicos zadas |
| DK1355919T3 (da) * | 2000-12-12 | 2011-03-14 | Medimmune Llc | Molekyler med lƦngere halveringstider, sammensƦtninger og anvendelser deraf |
| US6833441B2 (en) | 2001-08-01 | 2004-12-21 | Abmaxis, Inc. | Compositions and methods for generating chimeric heteromultimers |
| US6649055B1 (en) | 2002-05-07 | 2003-11-18 | The United States Of America As Represented By The United States Department Of Energy | Pump station for radioactive waste water |
| JP4794301B2 (ja) | 2003-06-11 | 2011-10-19 | äøå¤č£½č¬ę Ŗå¼ä¼ē¤¾ | ęä½ć®č£½é ę¹ę³ |
| WO2005073164A1 (en) * | 2004-01-30 | 2005-08-11 | Peplin Biolipids Pty Ltd | Therapeutic and carrier molecules |
| NZ549040A (en) | 2004-02-17 | 2009-07-31 | Schering Corp | Use for interleukin-33 (IL33) and the IL-33 receptor complex |
| CA2587627A1 (en) | 2004-11-15 | 2006-05-26 | Eli Lilly And Company | Desacyl ghrelin antibodies and therapeutic uses thereof |
| EP3050963B1 (en) | 2005-03-31 | 2019-09-18 | Chugai Seiyaku Kabushiki Kaisha | Process for production of polypeptide by regulation of assembly |
| CA2646965C (en) | 2006-03-24 | 2016-06-21 | Jonathan H. Davis | Engineered heterodimeric protein domains |
| US20090182127A1 (en) | 2006-06-22 | 2009-07-16 | Novo Nordisk A/S | Production of Bispecific Antibodies |
| US7560530B1 (en) | 2006-07-20 | 2009-07-14 | Schering Corporation | IL-33 receptor |
| EA201201533A1 (ru) | 2006-08-18 | 2014-11-28 | ŠŠ¾Š²Š°ŃŃŠøŃ ŠŠ³ | Prlr-ŃŠæŠµŃŠøŃŠøŃŠµŃŠŗŠ¾Šµ Š°Š½ŃŠøŃŠµŠ»Š¾ Šø ŠµŠ³Š¾ ŠæŃŠøŠ¼ŠµŠ½ŠµŠ½ŠøŃ |
| ES2667863T3 (es) | 2007-03-29 | 2018-05-14 | Genmab A/S | Anticuerpos biespecĆficos y mĆ©todos de producciĆ³n de los mismos |
| AU2008254704A1 (en) * | 2007-05-18 | 2008-11-27 | Medimmune, Llc | IL-33 in inflammatory disease |
| US8748356B2 (en) | 2007-10-19 | 2014-06-10 | Janssen Biotech, Inc. | Methods for use in human-adapting monoclonal antibodies |
| CN101970730A (zh) | 2007-12-19 | 2011-02-09 | ę£®ęē§å°å„„ē“¢ēē©ē§ęå ¬åø | éčæčåå°pā Øępā ¦ę„č®¾č®”åēęäŗŗä»å¤“pā Øå¬čä½å±ē¤ŗęåŗ,č½½ä½ćęä½åę¹ę³ |
| DE102007061963A1 (de) | 2007-12-21 | 2009-06-25 | Merck Patent Gmbh | Pyridazinonderivate |
| ES2563027T3 (es) | 2008-01-07 | 2016-03-10 | Amgen Inc. | MĆ©todo para fabricaciĆ³n de molĆ©culas heterodĆmeras Fc de anticuerpos utilizando efectos de conducciĆ³n electrostĆ”tica |
| JP5646457B2 (ja) | 2008-04-29 | 2014-12-24 | ć¢ćć“ć£ć»ć¤ć³ć³ć¼ćć¬ć¤ććć | äŗéåÆå¤ćć”ć¤ć³å ē«ć°ćććŖć³åć³ćć®ä½æēØ |
| JP2013516389A (ja) | 2009-01-06 | 2013-05-13 | ćć¤ć¢ććÆć¹ ć³ć¼ćć¬ć¼ć·ć§ć³ | ć«ćŖćÆć¬ć¤ć³é»å®³å¤ć«ććē²čēę²»ē |
| US8817596B2 (en) | 2009-01-09 | 2014-08-26 | Futurewei Technologies, Inc. | Protecting ingress and egress of a label switched path |
| US7879978B2 (en) * | 2009-03-31 | 2011-02-01 | Centocor Ortho Biotech, Inc. | Macaca fascicularis ST2L |
| EP2424567B1 (en) | 2009-04-27 | 2018-11-21 | OncoMed Pharmaceuticals, Inc. | Method for making heteromultimeric molecules |
| GB201005063D0 (en) | 2010-03-25 | 2010-05-12 | Ucb Pharma Sa | Biological products |
| SI2506871T1 (sl) | 2009-11-30 | 2016-12-30 | Janssen Biotech, Inc. | Mutanti Fc protitelesa z odstranjenimi efektorskimi funkcijami |
| US20110206672A1 (en) | 2010-02-25 | 2011-08-25 | Melvyn Little | Antigen-Binding Molecule And Uses Thereof |
| PH12012501884B1 (en) | 2010-03-30 | 2018-04-13 | Janssen Biotech Inc | Humanized il-25 antibodies |
| HUE027760T2 (en) | 2010-04-09 | 2016-11-28 | Critical Care Diagnostics Inc | Soluble human ST-2 antibodies and assays |
| US9150663B2 (en) | 2010-04-20 | 2015-10-06 | Genmab A/S | Heterodimeric antibody Fc-containing proteins and methods for production thereof |
| WO2011143545A1 (en) | 2010-05-14 | 2011-11-17 | Rinat Neuroscience Corporation | Heterodimeric proteins and methods for producing and purifying them |
| EP2420253A1 (en) | 2010-08-20 | 2012-02-22 | Leadartis, S.L. | Engineering multifunctional and multivalent molecules with collagen XV trimerization domain |
| JP6126991B2 (ja) | 2010-09-27 | 2017-05-10 | ć¤ć³ć»ć³ ćć¤ćŖćććÆļ¼ć¤ć³ć³ć¼ćć¬ć¼ććć | ććļ½ļ½åć³ć©ć¼ć²ć³ć«ēµåććęä½ |
| RU2604490C2 (ru) | 2010-11-05 | 2016-12-10 | ŠŠ°Š¹Š¼Š²Š¾ŃŠŗŃ ŠŠ½Šŗ. | ŠŠŠŠŠŠ Š£Š”Š¢ŠŠŠ§ŠŠŠŠŠ ŠŠŠ¢ŠŠ ŠŠŠŠŠŠ ŠŠŠŠ ŠŠŠ¢ŠŠ¢ŠŠŠ Š” ŠŠ£Š¢ŠŠ¦ŠŠÆŠŠ Š Fc ŠŠŠŠŠŠ |
| TW201238976A (en) | 2011-02-23 | 2012-10-01 | Hoffmann La Roche | Antibodies against human IL33R and uses thereof |
| US9212227B2 (en) * | 2012-04-30 | 2015-12-15 | Janssen Biotech, Inc. | ST2L antibody antagonists for the treatment of ST2L-mediated inflammatory pulmonary conditions |
| AR091069A1 (es) | 2012-05-18 | 2014-12-30 | Amgen Inc | Proteinas de union a antigeno dirigidas contra el receptor st2 |
-
2013
- 2013-03-13 US US13/798,226 patent/US9212227B2/en not_active Expired - Fee Related
- 2013-03-13 US US13/798,204 patent/US9090694B2/en not_active Expired - Fee Related
- 2013-04-29 SG SG10201608525SA patent/SG10201608525SA/en unknown
- 2013-04-29 ES ES13785158T patent/ES2755094T3/es active Active
- 2013-04-29 MX MX2014013200A patent/MX358134B/es active IP Right Grant
- 2013-04-29 NZ NZ702136A patent/NZ702136A/en not_active IP Right Cessation
- 2013-04-29 LT LT13785158T patent/LT2844292T/lt unknown
- 2013-04-29 CN CN201710188519.0A patent/CN107098973A/zh active Pending
- 2013-04-29 NZ NZ729913A patent/NZ729913A/en not_active IP Right Cessation
- 2013-04-29 HR HRP20191884TT patent/HRP20191884T1/hr unknown
- 2013-04-29 EA EA201891264A patent/EA201891264A3/ru unknown
- 2013-04-29 PT PT137851580T patent/PT2844292T/pt unknown
- 2013-04-29 EP EP13785158.0A patent/EP2844292B1/en active Active
- 2013-04-29 EP EP19192657.5A patent/EP3597219A1/en not_active Withdrawn
- 2013-04-29 WO PCT/US2013/038637 patent/WO2013165894A2/en not_active Ceased
- 2013-04-29 RS RS20191400A patent/RS59511B1/sr unknown
- 2013-04-29 CA CA2871948A patent/CA2871948C/en not_active Expired - Fee Related
- 2013-04-29 AU AU2013256645A patent/AU2013256645B2/en not_active Ceased
- 2013-04-29 KR KR1020207009560A patent/KR102147140B1/ko not_active Expired - Fee Related
- 2013-04-29 EA EA201491996A patent/EA031047B1/ru not_active IP Right Cessation
- 2013-04-29 CN CN201380035058.3A patent/CN104411333B/zh not_active Expired - Fee Related
- 2013-04-29 PL PL13785158T patent/PL2844292T3/pl unknown
- 2013-04-29 PE PE2014001920A patent/PE20150641A1/es active IP Right Grant
- 2013-04-29 SG SG11201407028WA patent/SG11201407028WA/en unknown
- 2013-04-29 NZ NZ74022113A patent/NZ740221A/en not_active IP Right Cessation
- 2013-04-29 HU HUE13785158A patent/HUE045864T2/hu unknown
- 2013-04-29 BR BR112014027165A patent/BR112014027165A2/pt active Search and Examination
- 2013-04-29 UA UAA201412805A patent/UA118336C2/uk unknown
- 2013-04-29 SM SM20190639T patent/SMT201900639T1/it unknown
- 2013-04-29 DK DK13785158.0T patent/DK2844292T3/da active
- 2013-04-29 KR KR1020147033310A patent/KR20150008152A/ko not_active Withdrawn
- 2013-04-29 JP JP2015510362A patent/JP6283354B2/ja not_active Expired - Fee Related
- 2013-04-29 SI SI201331591T patent/SI2844292T1/sl unknown
- 2013-04-29 MY MYPI2014703188A patent/MY166062A/en unknown
- 2013-04-30 TW TW108132205A patent/TWI700299B/zh not_active IP Right Cessation
- 2013-04-30 AR ARP130101485A patent/AR090909A1/es not_active Application Discontinuation
- 2013-04-30 TW TW102115440A patent/TWI589588B/zh not_active IP Right Cessation
- 2013-04-30 UY UY0001034774A patent/UY34774A/es unknown
- 2013-04-30 TW TW106115697A patent/TWI687440B/zh not_active IP Right Cessation
-
2014
- 2014-10-23 CR CR20140488A patent/CR20140488A/es unknown
- 2014-10-29 NI NI201400125A patent/NI201400125A/es unknown
- 2014-10-30 IL IL235401A patent/IL235401B/en active IP Right Grant
- 2014-10-30 CL CL2014002955A patent/CL2014002955A1/es unknown
- 2014-10-30 CO CO14240957A patent/CO7240389A2/es unknown
- 2014-10-30 PH PH12014502435A patent/PH12014502435A1/en unknown
- 2014-10-30 EC ECIEPI201425178A patent/ECSP14025178A/es unknown
- 2014-10-30 MX MX2018009430A patent/MX2018009430A/es unknown
-
2015
- 2015-11-12 US US14/939,624 patent/US9951137B2/en not_active Expired - Fee Related
-
2017
- 2017-04-20 AU AU2017202610A patent/AU2017202610B9/en not_active Ceased
- 2017-09-18 IL IL254569A patent/IL254569B/en active IP Right Grant
- 2017-11-06 JP JP2017213749A patent/JP6622274B2/ja not_active Expired - Fee Related
-
2018
- 2018-03-15 US US15/922,136 patent/US10450377B2/en not_active Expired - Fee Related
- 2018-08-29 PH PH12018501839A patent/PH12018501839A1/en unknown
-
2019
- 2019-05-24 JP JP2019097226A patent/JP2019162136A/ja not_active Withdrawn
- 2019-11-20 CY CY20191101218T patent/CY1122308T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12018501839A1 (en) | St2l antagonists and methods of use | |
| GB2527254B (en) | Benzylisoquinoline alkaloids (BIA) Producing microbes, and methods of making and using the same | |
| MY198562A (en) | Antibodies specifically binding pd-1 and their uses | |
| MX349630B (es) | Alfa-amilasas. | |
| PH12014502601A1 (en) | ANTI-Ly6E ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE | |
| MX2019008211A (es) | Estructuras fibrosas que comprenden particulas y metodos para fabricarlas. | |
| PH12015501627B1 (en) | Kv1.3 antagonists and methods of use | |
| PH12014501605A1 (en) | Anti-lrp5 antibodies and methods of use | |
| PH12016500598A1 (en) | Protoxin-ii variants and methods of use | |
| MX2017011223A (es) | Variantes de protoxina ii y metodos de uso. | |
| IN2014DN09798A (enExample) | ||
| MX2017012654A (es) | Variantes de protoxina-ii y metodos de uso. | |
| PH12016500826A1 (en) | Anti-ccl17 antibodies | |
| MX366815B (es) | Polioles, su preparaciĆ³n y su uso. | |
| MY184721A (en) | Use of odiparcil in the treatment of a mucopolysaccharidosis | |
| UA80618U (en) | Use of n-steroylethanolamine as radiomodifier | |
| IN2013CH00453A (enExample) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 29 APR 2019 BY THOMSON REUTERS Effective date: 20180321 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 29 APR 2020 BY THOMSON REUTERS Effective date: 20190319 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 29 APR 2021 BY THOMSON REUTERS Effective date: 20200317 |
|
| LAPS | Patent lapsed |